Search

This document was developed to enable greater consistency in the practice, application, and documentation of Model-Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of 'good practice' recommendations are assembled here in order to minimize the heterogeneity in both the quality and content of MID3 implementation and documentation. The three major objectives of this white paper are to: i) inform company decision makers how the strategic integration of MID3 can benefit R&D efficiency; ii) provide MID3 analysts with sufficient material to enhance the planning, rigor, and consistency of the application of MID3; and iii) provide regulatory authorities with substrate to develop MID3 related and/or MID3 enabled guidelines. [ABSTRACT FROM AUTHOR]

This tutorial aims at promoting good practices for exposure-response (E-R) analyses of clinical endpoints in drug development. The focus is on practical aspects of E-R analyses to assist modeling scientists with a process of performing such analyses in a consistent manner across individuals and projects and tailored to typical clinical drug development decisions. This includes general considerations for planning, conducting, and visualizing E-R analyses, and how these are linked to key questions.

Several new alpha-azido acids have been synthesized and their use in solid-phase peptide synthesis has been demonstrated. The azido group allows for high activation of the carboxyl group as an acid chloride without formation of byproducts and with no detectable racemization. An analog of Leu-enkephalin has been prepared and tested in the mouse vas deferens and guinea pig ileum bioassays: it displays moderate activity at the delta-opiod receptor.

Four chemotactic peptides, For-Met-Xxx-Phe-OMe, with an alpha,alpha-disubstituted amino acid at position 2 have been synthesized by the azido acid method [Meldal M, Juliano MA, Jansson AM. 1997. Azido acids in a novel method of solid-phase peptide synthesis. Tetrahedron Lett. 38: 2531-2534] on solid-phase, and were tested for biological activity. Dipropylglycine in the central position (Xxx) was found to be as active as the natural chemotactic peptide for chemotactic activity toward human neutrophils. Higher yields were obtained than previously reported solution-phase syntheses of chemotactic peptides, and EEDQ was used successfully for the difficult solid-phase formylation of amino groups.

A number of putative nicotinic acetylcholine receptor subunit clones were isolated by screening a lambda library of Caenorhabditis elegans genomic DNA with a probe derived from the Drosophila melanogaster ard gene (a non-alpha nicotinic acetylcholine receptor subunit clone). Studies on one of these loci, acr-2, are described; acr-2 is located between sup-7 and unc-6 on the X chromosome. A full-length cDNA was isolated and sequenced. The cDNA encodes a putative non-alpha subunit of a nicotinic acetylcholine receptor that shows many of the conserved features of vertebrate and invertebrate non-alpha nicotinic acetylcholine receptor subunits. To investigate the functional expression of the subunit, the corresponding cRNA was produced, in vitro, and micro-injected into Xenopus oocytes. When expressed alone acr-2 shows no levamisole-gated channel activity. When co-expressed with a C. elegans alpha subunit (unc-38), which is itself unable to form functional homo-oligomers, acr-2 contributed to the formation of a functional channel. This is the first functional expression of a nematode nicotinic acetylcholine receptor and supports the interpretation that the differentiation between alpha and non-alpha subunits dates back to the earliest stages of the evolution of the metazoa.